{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:02:45Z","timestamp":1792180965167,"version":"4.4.0"},"reference-count":148,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Neoadjuvant therapy has an established role in the treatment of patients with colorectal cancer. However, its role continues to evolve due to both advances in the available treatment modalities, and refinements in the indications for neoadjuvant treatment and subsequent surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A narrative review of the most recent relevant literature was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Short-course radiotherapy and long-course chemoradiotherapy have an established role in improving local but not systemic disease control in patients with rectal cancer. Total neoadjuvant therapy offers advantages over short-course radiotherapy and long-course chemoradiotherapy, not only in terms of increased local response but also in reducing the risk of systemic relapses. Non-operative management is increasingly preferred to surgery in patients with rectal cancer and clinical complete responses but is still associated with some negative impacts on functional outcomes. Neoadjuvant chemotherapy may be of some benefit in patients with locally advanced colon cancer with proficient mismatch repair, although patient selection is a major challenge. Neoadjuvant immunotherapy in patients with deficient mismatch repair cancers in the colon or rectum is altering the treatment paradigm for these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Neoadjuvant treatments for patients with colon or rectal cancers continue to evolve, increasing the complexity of decision-making for patients and clinicians alike. This review describes the current guidance and most recent developments.<\/jats:p><\/jats:sec>","DOI":"10.1093\/bjsopen\/zrae038","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:58:12Z","timestamp":1715763492000},"source":"Crossref","is-referenced-by-count":91,"title":["Neoadjuvant treatment of colorectal cancer: comprehensive review"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-4648","authenticated-orcid":false,"given":"Henry G","family":"Smith","sequence":"first","affiliation":[{"name":"Abdominalcenter K, Bispebjerg and Frederiksberg Hospital, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per J","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet and Dept. of Pelvic Cancer, Karolinska University Hospital , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D","family":"Shogan","sequence":"additional","affiliation":[{"name":"Department of Surgery, The University of Chicago Medicine , Chicago, Illinois , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deena","family":"Harji","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Manchester University NHS Foundation Trust , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario A. Gemelli-IRCCS , Rome , Italy"},{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche, Universita Cattolica del Sacro Cuore , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romano","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Fondazione Policlinico Universitario A. Gemelli-IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1990-2584","authenticated-orcid":false,"given":"Andreas","family":"Brandl","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplantation Surgery, University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Qvortrup","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospital, University of Copenhagen , Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2024062805110922200_zrae038-B1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/bjs.1800690515","article-title":"Local recurrence after low anterior resection using the staple gun","volume":"69","author":"Hurst","year":"1982","journal-title":"Br J Surg"},{"key":"2024062805110922200_zrae038-B2","first-page":"85","article-title":"Recurrence risk after stapled anastomosis for rectal carcinoma","volume":"150","author":"Lasson","year":"1984","journal-title":"Acta Chir Scand"},{"key":"2024062805110922200_zrae038-B3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/bjs.1800691019","article-title":"The mesorectum in rectal cancer surgery\u2014the clue to pelvic recurrence?","volume":"69","author":"Heald","year":"1982","journal-title":"Br J Surg"},{"key":"2024062805110922200_zrae038-B4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(86)91510-2","article-title":"Recurrence and survival after total mesorectal excision for rectal cancer","volume":"1","author":"Heald","year":"1986","journal-title":"Lancet"},{"key":"2024062805110922200_zrae038-B5","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/archsurg.133.8.894","article-title":"Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978\u20131997","volume":"133","author":"Heald","year":"1998","journal-title":"Arch Surg"},{"key":"2024062805110922200_zrae038-B6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00000658-199002000-00011","article-title":"Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial","volume":"211","author":"P\u00e5hlman","year":"1990","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B7","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","article-title":"Improved survival with preoperative radiotherapy in resectable rectal cancer","volume":"336","author":"Swedish Rectal Cancer Trial","year":"1997","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer","volume":"345","author":"Kapiteijn","year":"2001","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B10","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","article-title":"Chemotherapy with preoperative radiotherapy in rectal cancer","volume":"355","author":"Bosset","year":"2006","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B12","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B13","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet"},{"key":"2024062805110922200_zrae038-B14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1148\/radiology.211.1.r99ap35215","article-title":"Rectal carcinoma: thin-section MR imaging for staging in 28 patients","volume":"211","author":"Brown","year":"1999","journal-title":"Radiology"},{"key":"2024062805110922200_zrae038-B15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/bjs.4034","article-title":"Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging","volume":"90","author":"Brown","year":"2003","journal-title":"Br J Surg"},{"key":"2024062805110922200_zrae038-B16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.38937.646400.55","article-title":"Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study","volume":"333","author":"MERCURY Study Group","year":"2006","journal-title":"BMJ"},{"key":"2024062805110922200_zrae038-B17","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/SLA.0b013e31820b8d52","article-title":"Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study","volume":"253","author":"Taylor","year":"2011","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1200\/JCO.2012.45.3258","article-title":"Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study","volume":"32","author":"Taylor","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B19","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","article-title":"Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients\u2014a Dutch colorectal cancer group study","volume":"23","author":"Peeters","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B20","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1200\/JCO.2005.05.256","article-title":"Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial","volume":"23","author":"Marijnen","year":"2005","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1200\/JCO.18.00032","article-title":"Neoadjuvant (chemo)radiotherapy with total mesorectal excision only is not sufficient to prevent lateral local recurrence in enlarged nodes: results of the multicenter lateral node study of patients with low cT3\/4 rectal cancer","volume":"37","author":"Ogura","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B22","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1245\/s10434-011-2036-1","article-title":"Adverse features on rectal MRI identify a high-risk group that may benefit from more intensive preoperative staging and treatment","volume":"19","author":"Hunter","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2024062805110922200_zrae038-B23","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00330-017-5026-2","article-title":"Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting","volume":"28","author":"Beets-Tan","year":"2018","journal-title":"Eur Radiol"},{"key":"2024062805110922200_zrae038-B24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/codi.13565","article-title":"The degree of extramural spread of T3 rectal cancer: an appeal to the American Joint Committee on Cancer","volume":"19","author":"Zinicola","year":"2017","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.dld.2017.01.152","article-title":"Rectal cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO)","volume":"49","author":"G\u00e9rard","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2024062805110922200_zrae038-B26","doi-asserted-by":"crossref","first-page":"iv263","DOI":"10.1093\/annonc\/mdy161","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Glynne-Jones","year":"2018","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B27","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.6004\/jnccn.2022.0051","article-title":"Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Benson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2024062805110922200_zrae038-B28","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1093\/annonc\/mdu029","article-title":"EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy","volume":"25","author":"Chand","year":"2014","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B29","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","article-title":"Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer","volume":"93","author":"Bujko","year":"2006","journal-title":"Br J Surg"},{"key":"2024062805110922200_zrae038-B30","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2012.42.9597","article-title":"Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04","volume":"30","author":"Ngan","year":"2012","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B31","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2007.15.3858","article-title":"Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer","volume":"26","author":"Braendengen","year":"2008","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B32","first-page":"100562","article-title":"Preoperative short-course radiation therapy with PROtons compared to photons in high-risk RECTal cancer (PRORECT): initial dosimetric experience","volume":"39","author":"Pedone","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024062805110922200_zrae038-B33","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(14)71199-4","article-title":"Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Breugom","year":"2015","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11864-022-00961-5","article-title":"The evolving neoadjuvant treatment paradigm for patients with locoregional mismatch repair proficient rectal cancer","volume":"23","author":"Bhudia","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2024062805110922200_zrae038-B35","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B36","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B38","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared with long-course chemoradiotherapy and surgery: a 5-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41571-023-00751-4","article-title":"TNT and local recurrence in the RAPIDO trial\u2014untangling the puzzle","volume":"20","author":"Glynne-Jones","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"2024062805110922200_zrae038-B40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.radonc.2013.05.009","article-title":"Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO\/ARO\/AIO-94 phase III trial","volume":"108","author":"Wolff","year":"2013","journal-title":"Radiother Oncol"},{"key":"2024062805110922200_zrae038-B41","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B42","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT trial (alliance N1048)","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B43","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.2016.66.6198","article-title":"Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial","volume":"34","author":"Deng","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B44","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant modified FOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: final results of the Chinese FOWARC trial","volume":"37","author":"Deng","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/SLA.0000000000005780","article-title":"Neoadjuvant chemotherapy with CAPOX versus chemoradiation for locally advanced rectal cancer with uninvolved mesorectal fascia (CONVERT): initial results of a phase III trial","volume":"277","author":"Mei","year":"2023","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B46","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S1470-2045(10)70172-8","article-title":"Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data","volume":"11","author":"Maas","year":"2010","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B47","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ejso.2018.04.007","article-title":"Number of lymph nodes assessed has no prognostic impact in node-negative rectal cancers after neoadjuvant therapy. Results of the \u2018Italian Society of Surgical Oncology (S.I.C.O.) Colorectal Cancer Network\u2019 (SICO-CCN) multicentre collaborative study","volume":"44","author":"Degiuli","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"2024062805110922200_zrae038-B48","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B49","first-page":"1","article-title":"Could the conservative approach be considered safe in the treatment of locally advanced rectal cancer in case of a clinical near-complete or complete response? A retrospective analysis","volume":"28","author":"Chiloiro","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"2024062805110922200_zrae038-B50","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B51","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/S0140-6736(18)31078-X","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"2024062805110922200_zrae038-B52","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/SLA.0000000000002761","article-title":"Oncological and survival outcomes in watch and wait patients with a clinical complete response after neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and pooled analysis","volume":"268","author":"Dattani","year":"2018","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B53","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062805110922200_zrae038-B54","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1080\/0284186X.2017.1327721","article-title":"The feasibility of short-course radiotherapy in a watch-and-wait policy for rectal cancer","volume":"56","author":"Bujko","year":"2017","journal-title":"Acta Oncol"},{"key":"2024062805110922200_zrae038-B55","doi-asserted-by":"crossref","first-page":"zrab093","DOI":"10.1093\/bjsopen\/zrab093","article-title":"Organ preservation following short-course radiotherapy for rectal cancer","volume":"5","author":"Nilsson","year":"2021","journal-title":"BJS Open"},{"key":"2024062805110922200_zrae038-B56","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1200\/JCO.22.00032","article-title":"Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B57","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/JCO.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B58","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(17)31056-5","article-title":"Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial","volume":"390","author":"Rullier","year":"2017","journal-title":"Lancet"},{"key":"2024062805110922200_zrae038-B59","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1111\/codi.16742","article-title":"Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group","volume":"25","author":"Calmels","year":"2023","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S2468-1253(20)30333-2","article-title":"Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study","volume":"6","author":"Bach","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062805110922200_zrae038-B61","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/codi.16056","article-title":"Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC)? Protocol for the international, multicentre, rolling phase II\/III partially randomized patient preference trial evaluating long-course concurrent chemoradiotherapy versus short-course radiotherapy organ preservation approaches","volume":"24","author":"Bach","year":"2022","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B62","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/codi.12627","article-title":"Report from a consensus meeting: response to chemoradiotherapy in rectal cancer\u2014predictor of cure and a crucial new choice for the patient: on behalf of the Champalimaud 2014 faculty for \u2018Rectal cancer: when NOT to operate\u2019","volume":"16","author":"Heald","year":"2014","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B63","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S2468-1253(18)30301-7","article-title":"Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis","volume":"3","author":"Chadi","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062805110922200_zrae038-B64","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/SLA.0000000000003286","article-title":"Conditional survival in patients with rectal cancer and complete clinical response managed by watch and wait after chemoradiation: recurrence risk over time","volume":"272","author":"S\u00e3o Juli\u00e3o","year":"2020","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B65","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13244-021-01055-w","article-title":"Re-staging and follow-up of rectal cancer patients with MR imaging when \u2018watch-and-wait\u2019 is an option: a practical guide","volume":"12","author":"Santiago","year":"2021","journal-title":"Insights Imaging"},{"key":"2024062805110922200_zrae038-B66","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/DCR.0000000000002259","article-title":"Delayed TME surgery in a watch-and-wait strategy after neoadjuvant chemoradiotherapy for rectal cancer: an analysis of hospital costs and surgical and oncological outcomes","volume":"66","author":"Meyer","year":"2023","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B67","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.ejso.2019.04.006","article-title":"Salvage surgery for local regrowths in watch & wait\u2014are we harming our patients by deferring the surgery?","volume":"45","author":"Nasir","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2024062805110922200_zrae038-B68","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.3390\/cancers14133071","article-title":"Role of local excision for suspected regrowth in a watch and wait strategy for rectal cancer","volume":"14","author":"Geubels","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024062805110922200_zrae038-B69","doi-asserted-by":"crossref","first-page":"101574","DOI":"10.1016\/j.suronc.2021.101574","article-title":"Rectal cancer: watch-and-wait and continuing the rectal-preserving strategy with local excision for incomplete response or limited regrowth","volume":"37","author":"Al-Najami","year":"2021","journal-title":"Surg Oncol"},{"key":"2024062805110922200_zrae038-B70","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/DCR.0000000000002197","article-title":"Outcomes of patients with local regrowth after nonoperative management of rectal cancer after neoadjuvant chemoradiotherapy","volume":"65","author":"Cotti","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B71","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/DCR.0000000000001707","article-title":"Salvage surgery with organ preservation for patients with local regrowth after watch and wait: is it still possible?","volume":"63","author":"Fernandez","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B72","doi-asserted-by":"crossref","DOI":"10.1177\/15330338221105156","article-title":"Effects of preoperative radiotherapy on long-term bowel function in patients with rectal cancer treated with anterior resection: a systematic review and meta-analysis","volume":"21","author":"Liang","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"2024062805110922200_zrae038-B73","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/codi.15554","article-title":"Urinary dysfunction after colorectal cancer treatment and impact on quality of life\u2014a national cross-sectional study in males","volume":"23","author":"Kristensen","year":"2021","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B74","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.clon.2022.07.003","article-title":"Effect of neoadjuvant therapy on the functional outcome of patients with rectal cancer: a systematic review and meta-analysis","volume":"35","author":"Li","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2024062805110922200_zrae038-B75","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.ejso.2021.03.251","article-title":"Risk factors for sexual dysfunction after rectal cancer surgery in 948 consecutive patients: a prospective cohort study","volume":"47","author":"Li","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"2024062805110922200_zrae038-B76","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.1097\/SLA.0000000000003806","article-title":"The incidence of low anterior resection syndrome as assessed in an international randomized controlled trial (MRC\/NIHR ROLARR)","volume":"274","author":"Bolton","year":"2021","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B77","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijsu.2018.06.031","article-title":"A meta-analysis of the prevalence of low anterior resection syndrome and systematic review of risk factors","volume":"56","author":"Croese","year":"2018","journal-title":"Int J Surg"},{"key":"2024062805110922200_zrae038-B78","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/codi.14784","article-title":"Urinary dysfunction in patients with rectal cancer: a prospective cohort study","volume":"22","author":"Karlsson","year":"2020","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/codi.12758","article-title":"Urinary and sexual dysfunction in women after resection with and without preoperative radiotherapy for rectal cancer: a population-based cross-sectional study","volume":"17","author":"Bregendahl","year":"2015","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B80","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/COC.0000000000000923","article-title":"Nonoperative management following complete response in rectal cancer after short-course radiation therapy and consolidation chemotherapy: clinical outcomes and quality of life measures","volume":"45","author":"Reddy","year":"2022","journal-title":"Am J Clin Oncol"},{"key":"2024062805110922200_zrae038-B81","first-page":"340","article-title":"Better quality of life and reduced fecal incontinence in rectal cancer patients with the watch-and-wait follow-up strategy","volume":"86","author":"Pascual-Russo","year":"2021","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"2024062805110922200_zrae038-B82","doi-asserted-by":"crossref","first-page":"djw171","DOI":"10.1093\/jnci\/djw171","article-title":"Long-term outcome of an organ preservation program after neoadjuvant treatment for rectal cancer","volume":"108","author":"Martens","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"2024062805110922200_zrae038-B83","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/DCR.0000000000001646","article-title":"Patient-reported bowel function in patients with rectal cancer managed by a watch-and-wait strategy after neoadjuvant therapy: a case\u2013control study","volume":"63","author":"Quezada-Diaz","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B84","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/DCR.0000000000000862","article-title":"Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection\u2014a matched-controlled study","volume":"60","author":"Hupkens","year":"2017","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B85","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/DCR.0000000000000543","article-title":"Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation","volume":"59","author":"Habr-Gama","year":"2016","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B86","doi-asserted-by":"crossref","first-page":"e230146","DOI":"10.1001\/jamasurg.2023.0146","article-title":"Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach","volume":"158","author":"Custers","year":"2023","journal-title":"JAMA Surg"},{"key":"2024062805110922200_zrae038-B87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","author":"U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"2024062805110922200_zrae038-B88","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/codi.15838","article-title":"Burden of disease experienced by patients following a watch-and-wait policy for locally advanced rectal cancer: a qualitative study","volume":"23","author":"Pennings","year":"2021","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B89","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B90","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/DCR.0000000000002323","article-title":"The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer","volume":"65","author":"Vogel","year":"2022","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/codi.15971","article-title":"The significance of subdivisions of microscopically positive (R1) margins in colorectal cancer: a retrospective study of a national cancer registry","volume":"24","author":"Smith","year":"2022","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B92","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/codi.16121","article-title":"The impact of subdivisions of microscopically positive (R1) margins on patterns of relapse in stage III colorectal cancer\u2014a retrospective cohort study","volume":"24","author":"Smith","year":"2022","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B93","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B94","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/0284186X.2023.2218555","article-title":"Differences in adjuvant chemotherapy and oncological outcomes according to margin status in patients with stage III colon cancer","volume":"62","author":"Smith","year":"2023","journal-title":"Acta Oncol"},{"key":"2024062805110922200_zrae038-B95","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/SLA.0000000000003454","article-title":"Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22)","volume":"271","author":"Karoui","year":"2020","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B96","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/codi.15585","article-title":"Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk stage II and III colon cancers? Three years\u2019 follow-up results of the PRODIGE 22 phase II randomized multicentre trial","volume":"23","author":"Karoui","year":"2021","journal-title":"Colorectal Dis"},{"key":"2024062805110922200_zrae038-B97","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1200\/JCO.22.00046","article-title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial","volume":"41","author":"Morton","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B98","doi-asserted-by":"crossref","first-page":"LBA3503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3503","article-title":"Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: the NeoCol trial","volume":"41","author":"Jensen","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B99","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdu141","article-title":"Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer","volume":"25","author":"Douillard","year":"2014","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B100","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B101","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00384-017-2932-3","article-title":"Staging with computed tomography of patients with colon cancer","volume":"33","author":"Malmstrom","year":"2018","journal-title":"Int J Colorectal Dis"},{"key":"2024062805110922200_zrae038-B102","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B103","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"key":"2024062805110922200_zrae038-B104","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ejso.2013.10.001","article-title":"Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer","volume":"40","author":"van Gestel","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2024062805110922200_zrae038-B105","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1245\/s10434-017-6037-6","article-title":"Locally advanced colorectal cancer: true peritoneal tumor penetration is associated with peritoneal metastases","volume":"25","author":"Klaver","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2024062805110922200_zrae038-B106","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/DCR.0b013e318197e351","article-title":"Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population","volume":"52","author":"Cheynel","year":"2009","journal-title":"Dis Colon Rectum"},{"key":"2024062805110922200_zrae038-B107","doi-asserted-by":"crossref","first-page":"106976","DOI":"10.1016\/j.ejso.2023.07.002","article-title":"A narrative review of what can HIPEC do","volume":"49","author":"Sugarbaker","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"2024062805110922200_zrae038-B108","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024062805110922200_zrae038-B109","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study","volume":"21","author":"Go\u00e9r\u00e9","year":"2020","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B110","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Quenet","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024062805110922200_zrae038-B111","doi-asserted-by":"crossref","first-page":"1122755","DOI":"10.3389\/fonc.2023.1122755","article-title":"Elevated temperatures and longer durations improve the efficacy of oxaliplatin- and mitomycin C-based hyperthermic intraperitoneal chemotherapy in a confirmed rat model for peritoneal metastasis of colorectal cancer origin","volume":"13","author":"Helderman","year":"2023","journal-title":"Front Oncol"},{"key":"2024062805110922200_zrae038-B112","doi-asserted-by":"crossref","first-page":"zraa075","DOI":"10.1093\/bjsopen\/zraa075","article-title":"Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study","volume":"5","author":"Prabhu","year":"2021","journal-title":"BJS Open"},{"key":"2024062805110922200_zrae038-B113","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamasurg.2023.0662","article-title":"Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial","volume":"158","author":"Arjona-S\u00e1nchez","year":"2023","journal-title":"JAMA Surg"},{"key":"2024062805110922200_zrae038-B114","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B115","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"2024062805110922200_zrae038-B116","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/j.annonc.2022.08.016","article-title":"LBA7\u2014neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study","volume":"33","author":"Chalabi","year":"2022","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B117","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2024062805110922200_zrae038-B118","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/35105024","article-title":"T-cell regulation by CD28 and CTLA-4","volume":"1","author":"Alegre","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"2024062805110922200_zrae038-B119","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"2024062805110922200_zrae038-B120","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B121","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B122","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2024062805110922200_zrae038-B123","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"2024062805110922200_zrae038-B124","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"2024062805110922200_zrae038-B125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"2024062805110922200_zrae038-B126","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2024062805110922200_zrae038-B127","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"2024062805110922200_zrae038-B128","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","article-title":"The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer","volume":"130","author":"Ward","year":"2016","journal-title":"Adv Immunol"},{"key":"2024062805110922200_zrae038-B129","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B130","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B131","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B132","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2024062805110922200_zrae038-B133","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"2024062805110922200_zrae038-B134","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"2024062805110922200_zrae038-B135","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"2024062805110922200_zrae038-B136","doi-asserted-by":"crossref","first-page":"108286","DOI":"10.1016\/j.ijscr.2023.108286","article-title":"Challenges presented by complete response to immune checkpoint blockade in patients with dMMR colorectal cancer: a case report","volume":"106","author":"Smith","year":"2023","journal-title":"Int J Surg Case Rep"},{"key":"2024062805110922200_zrae038-B137","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1136\/gutjnl-2015-310101","article-title":"Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis","volume":"65","author":"Mima","year":"2016","journal-title":"Gut"},{"key":"2024062805110922200_zrae038-B138","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"2024062805110922200_zrae038-B139","doi-asserted-by":"crossref","first-page":"109886","DOI":"10.1016\/j.celrep.2021.109886","article-title":"Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models","volume":"37","author":"Dong","year":"2021","journal-title":"Cell Rep"},{"key":"2024062805110922200_zrae038-B140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ccell.2022.11.013","article-title":"Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer","volume":"41","author":"Teng","year":"2023","journal-title":"Cancer Cell"},{"key":"2024062805110922200_zrae038-B141","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ccell.2021.07.002","article-title":"Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy","volume":"39","author":"Shiao","year":"2021","journal-title":"Cancer Cell"},{"key":"2024062805110922200_zrae038-B142","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-20-3445","article-title":"Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a prospective, longitudinal study","volume":"27","author":"Yi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2024062805110922200_zrae038-B143","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/SLA.0000000000006015","article-title":"Young-onset rectal cancer: unique tumoral microbiome and correlation with response to neoadjuvant therapy","volume":"278","author":"White","year":"2023","journal-title":"Ann Surg"},{"key":"2024062805110922200_zrae038-B144","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"key":"2024062805110922200_zrae038-B145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41416-020-0941-4","article-title":"Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence","volume":"123","author":"Murahashi","year":"2020","journal-title":"Br J Cancer"},{"key":"2024062805110922200_zrae038-B146","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"2024062805110922200_zrae038-B147","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1078-0432.CCR-21-2404","article-title":"Circulating tumor DNA in stage III colorectal cancer, beyond minimal residual disease detection, toward assessment of adjuvant therapy efficacy and clinical behavior of recurrences","volume":"28","author":"Henriksen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024062805110922200_zrae038-B148","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","article-title":"Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer\u2014evaluation in a nationwide Danish cohort","volume":"35","author":"Henriksen","year":"2023","journal-title":"Ann Oncol"}],"container-title":["BJS Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/8\/3\/zrae038\/58347050\/zrae038.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjsopen\/article-pdf\/8\/3\/zrae038\/58347050\/zrae038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T22:44:42Z","timestamp":1731624282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjsopen\/article\/doi\/10.1093\/bjsopen\/zrae038\/7673144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,8]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/bjsopen\/zrae038","relation":{},"ISSN":["2474-9842"],"issn-type":[{"value":"2474-9842","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,5,8]]},"article-number":"zrae038"}}